| 000 | 01774 a2200517 4500 | ||
|---|---|---|---|
| 005 | 20250518015056.0 | ||
| 264 | 0 | _c20190524 | |
| 008 | 201905s 0 0 eng d | ||
| 022 | _a1942-5546 | ||
| 024 | 7 |
_a10.1016/j.mayocp.2018.08.034 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aZonozi, Reza | |
| 245 | 0 | 0 |
_aElevated Vancomycin Trough Levels in a Tertiary Health System: Frequency, Risk Factors, and Prognosis. _h[electronic resource] |
| 260 |
_bMayo Clinic proceedings _c01 2019 |
||
| 300 |
_a17-26 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Multicenter Study; Research Support, N.I.H., Extramural | ||
| 650 | 0 | 4 |
_aAcute Kidney Injury _xchemically induced |
| 650 | 0 | 4 | _aAdministration, Intravenous |
| 650 | 0 | 4 |
_aAnti-Bacterial Agents _xadministration & dosage |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFollow-Up Studies |
| 650 | 0 | 4 |
_aGlomerular Filtration Rate _xdrug effects |
| 650 | 0 | 4 |
_aHospital Mortality _xtrends |
| 650 | 0 | 4 |
_aHospitalization _xtrends |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aIncidence |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aPrognosis |
| 650 | 0 | 4 | _aRetrospective Studies |
| 650 | 0 | 4 |
_aRisk Assessment _xmethods |
| 650 | 0 | 4 | _aRisk Factors |
| 650 | 0 | 4 | _aTime Factors |
| 650 | 0 | 4 |
_aUnited States _xepidemiology |
| 650 | 0 | 4 |
_aVancomycin _xadministration & dosage |
| 700 | 1 | _aWu, Aozhou | |
| 700 | 1 | _aShin, Jung-Im | |
| 700 | 1 | _aSecora, Alex | |
| 700 | 1 | _aCoresh, Josef | |
| 700 | 1 | _aInker, Lesley A | |
| 700 | 1 | _aChang, Alex R | |
| 700 | 1 | _aGrams, Morgan E | |
| 773 | 0 |
_tMayo Clinic proceedings _gvol. 94 _gno. 1 _gp. 17-26 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.mayocp.2018.08.034 _zAvailable from publisher's website |
| 999 |
_c29223026 _d29223026 |
||